<DOC>
	<DOCNO>NCT00333164</DOCNO>
	<brief_summary>Multi-center , open-labelled randomize controlled trial , study effect aspirin plus cilostazol aspirin alone progression intracranial arterial stenosis , 200 chronic stroke patient 50-99 % stenosis , follow 2 year</brief_summary>
	<brief_title>Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis</brief_title>
	<detailed_description>Intracraial arterial stenosis ( IAS ) common Asia , include Japanese , Cocasian . Also , stroke recurrence rate high patient lesion , despite medical treatment . Accoding result WASID ( N Engl J Med 2005 ; 352:1305-16 ) , warfarin recommend concern safety ( high risk intracranial hemorrhage death compare aspirin ) , wheras efficacy aspirin enough symptomatic IAS patient . Under condition , plan conduct nationwide multi-center , open label , randomize control trial compare effect aspirin plus cilostazol ( phosphodiestrase type 3 inhibitor ) aspirin alone progression IAS 200 IAS patient ischemic stroke 2 week 6 month onset . Patients randomly allocate either two group . Aspirin 100mg/day plus cilostazol 200 mg/day give 100 patient one group , aspirin 100 mg/day alone give 100 patient another group . Follow-up period least two year . The primary endpoint progression IAS MRA two year randomization . The secondary endpoint cardiovascular event ( ischemic stroke , myocardial infarct , vascular event ) , death , serious adverse event , new silent brain infarct , activity daily life . The purpose study establish best medical treatment symptomatic IAS patient . This study also provide important information future randomize control study compare medical treatment alone intravascular intervetnion ( PTA and/or stenting ) patient .</detailed_description>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>( 1 ) Ischemic stroke two week six month onset , ( 2 ) Responsible lesion identify MRI , ( 3 ) Intracranial arterial stenosis &gt; 50 % MRA territory responsible lesion , ( 4 ) Intracranial arterial stenosis suproclinoid internal carotid arterry , M1 portion midlle cerebral artery , basilar artery , ( 5 ) Age 45 85 year , ( 6 ) Able visit outpatient clinic , ( 7 ) Written informed consent obtain patient family . ( 1 ) Patients potential cardiac embolic source , ( 2 ) Patients receive cilostazol , ( 3 ) Patients warfarin treatment , ( 4 ) Patients MRI perfomed , ( 5 ) Patients PTA bypass surgery plan , ( 6 ) Patients history symptomatic intracranial hemorrhage , hemorrhagic disease ( active peptic ulcer etc . ) , hemophilia coagulation abnormality , ( 7 ) Patients hypersensitivity cilostazol aspirin , ( 8 ) Patients congestive heart failure uncontrollable angina pectoris , ( 9 ) Patients thrombocytopenia ( &lt; 100,000/mm3 ) , ( 10 ) Patients liver dysfunction ( AST ALT &gt; 100 IU/L ) , ( 11 ) Patients renal dysfunction ( Creatinin &gt; 2.0 mg/dl ) , ( 12 ) Patients follow study period , ( 13 ) Patients enrol clinical trial , ( 14 ) Patients inadequate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>intracranial arteriosclerosis</keyword>
	<keyword>cilostazol</keyword>
	<keyword>Platelete aggrigation inhibitor dual antiplatelet therapy</keyword>
	<keyword>Drug therapy , combination</keyword>
	<keyword>Clinical trial</keyword>
</DOC>